Notice of Expansion of Licensed Field under Amended and Restated License Agreement between Bellicum Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. has notified ARIAD Pharmaceuticals, Inc. that, under their existing license agreement, it is expanding its exclusive rights to include all cancer indications except prostate cancer. This notice is given in accordance with the terms of their March 7, 2011 agreement, following a qualified financing that closed on March 7, 2012. The key obligation is the formal expansion of the licensed field, granting Bellicum additional exclusive rights as specified in the agreement.
Exhibit 10.14
NOTICE OF EXPANSION OF LICENSED FIELD TO OBTAIN ADDITIONAL EXCLUSIVE RIGHTS
This Notice of Expansion of Licensed Field to Obtain Additional Exclusive Rights (“Notice”) is delivered pursuant to Section 2.1.2(a) of the Amended and Restated License Agreement, dated March 7, 2011 (“Agreement”) by and between Bellicum Pharmaceuticals, Inc. (the “Company”) and ARIAD Pharmaceuticals, Inc. All capitalized terms not otherwise defined herein shall have the meanings as set forth in the Agreement.
The closing date of the Qualified Financing was March 7th, 2012.
All cancer indications (other than prostate cancer) are to be included in the Additional Indications to the Licensed Field.
| BELLICUM PHARMACEUTICALS, INC. | ||
| By: | /s/ Thomas J. Farrell | |
| Name: | Thomas J. Farrell | |
| Title: | President & Chief Executive Officer | |
| Address: | 6400 Fannin Street, Suite 2300 | |
| Houston, TX 77030 | ||
